Get the Stockscreener App
6.816
4.54%
-0.324
After Hours:
6.82
0.004
+0.06%
Neuphoria Therapeutics Inc stock is traded at $6.816, with a volume of 13,298.
It is down -4.54% in the last 24 hours and up +36.59% over the past month.
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
See More
Previous Close:
$7.14
Open:
$7.19
24h Volume:
13,298
Relative Volume:
0.50
Market Cap:
$12.92M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.79%
1M Performance:
+36.59%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$6.60
$7.19
1-Week Range:
$6.60
$7.28
52-Week Range:
$2.90
$12.55
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
6.816 | 12.92M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Neuphoria to Present at the American Society of Clinical Psychop - GuruFocus
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting | NEUP Stock News - GuruFocus
Neuphoria Therapeutics to Present BNC210 Phase 2b Data at ASCP 2025 Annual Meeting - Nasdaq
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting - GlobeNewswire
Neuphoria Provides First Quarter 2025 Business Updates | NEUP St - GuruFocus
Neuphoria Therapeutics Inc. Reports Q1 2025 Progress and Upcoming Milestones for BNC210 and MK-1167 Programs - Nasdaq
Neuphoria Provides First Quarter 2025 Business Updates - GlobeNewswire
Neuphoria Therapeutics Says Cash Runway Extends Into Q3 2026SEC Filing - marketscreener.com
Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView
Neuphoria Therapeutics Delays 10-Q Filing - TipRanks
Neuphoria Therapeutics (NEUP) Outlines Robust 2025 Drug Developm - GuruFocus
Neuphoria Therapeutics IncMerck Pays $15M Milestone, Extends Cash Runway To Q3 2026 - marketscreener.com
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans - GlobeNewswire
Neuphoria receives $15M milestone payment from Merck - MSN
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025 - GlobeNewswire
Neuphoria Therapeutics Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Neuphoria Therapeutics Inc Rings the Opening Bell - Nasdaq
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes - MSN
Neuphoria Therapeutics’ Listing on Nasdaq - Global Legal Chronicle
Neuphoria Therapeutics Inc. (NEUP) reports earnings - Quartz
Neuphoria Therapeutics rises on $15 mln milestone payment from Merck - TradingView
Neuphoria Therapeutics shares surge on $15M Merck payment - MSN
Neuphoria To Receive $15 Mln Milestone Payment From Merck; Stock Up In Pre-market - Nasdaq
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewswire
Neuphoria Therapeutics to receive $15M milestone payment from Merck - MSN
Neuphoria Therapeutics shares surge on $15M Merck payment By Investing.com - Investing.com Australia
Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going - MSN
Neuphoria Therapeutics Takes the Biotech Spotlight: U.S. Relocation and Nasdaq Debut Promise Game-Changing Opportunities - Jomfruland.net
Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Given New $21.00 Price Target at HC Wainwright - Armenian Reporter
Brokers Set Expectations for NEUP Q2 Earnings - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Stock - Defense World
FY2027 Earnings Estimate for NEUP Issued By HC Wainwright - Defense World
Why Neuphoria Therapeutics Inc. (NEUP) Surged on Friday - MSN
10 Firms Defy Market Pessimism - Insider Monkey
Stock market news: Nvni Group +254.36%, Allurion Technologies +153.92% among top gainers during mid day trading - Business Upturn
Stock market news: Neuphoria Therapeutics and Nvni Group saw surge of 134.96% and 245.64% concurrently during mid day trading - Business Upturn
Neuphoria Therapeutics regains Nasdaq compliance - Investing.com India
Neuphoria Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Australia
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder - Marketscreener.com
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
There is no financial data for Neuphoria Therapeutics Inc (NEUP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):